AI Article Synopsis
Article Abstract
We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the Plasmodium vivax circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A-E): four groups (A-D) were immunized intramuscularly with 50 and 100 μg/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in > 90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032485 | PMC |
| http://dx.doi.org/10.4269/ajtmh.2011.09-0516 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cocktail vaccine for the management of and .
Front Immunol
December 2024
Entomology Laboratory, Division of Parasitology, Indian Council of Agricultural Research (ICAR)- Indian Veterinary Research Institute (IVRI)-Izatnagar, Bareilly, Uttar Pradesh, India.
Introduction: Globally, ticks rank second only to mosquitoes as vectors of deadly pathogens affecting humans and first in transmitting animal pathogens, presenting a significant challenge to human wellness and sustainability of livestock-based industries. Traditional tick control via chemical acaricides impacts on the environment and has led to the emergence of multi-acaricide-resistant tick populations. Use of immunoprophylactic, along with other components of integrated tick management, holds the potential to mitigate tick infestations in a sustainable manner.
View Article and Find Full Text PDFOptimum processing conditions for a trivalent-inactivated bovine viral diarrhea virus (BVDV) vaccine using field strains and immunogenicity of candidate formulations with different adjuvants.
Vet Res Commun
November 2024
Department of Virology, Bursa Uludag University, Faculty of Veterinary Medicine, 16059, Bursa, Türkiye.
Bovine viral diarrhea virus (BVDV) is among the common bovine pathogens worldwide. One of the prominent protection measures of BVDV is vaccination. This study aimed to determine the growth characteristics, inactivation kinetics of vaccine candidates using local BVDV strains [TR-26 (BVDV-1f), TR-21 (BVDV-1l), and TR-15 (BVDV-2b)], and the serological response in experimental animals to inactivated BVDV vaccine formulations prepared with different adjuvants.
View Article and Find Full Text PDFAML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Front Oncol
October 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Article Synopsis
- Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
- A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
- The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice.
Vaccines (Basel)
October 2024
Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94551, USA.
Article Synopsis
- - Chlamydia is a widespread bacterial STD that often goes unnoticed, creating a need for a preventive vaccine to address its serious health risks.
- - Cell-free protein synthesis (CFPS) allows for quick and adaptable production of vaccine proteins, demonstrated by producing the chlamydial CT584 protein for testing in mice.
- - Although CT584 prompted strong antibody responses, it failed to effectively protect against chlamydia infection, highlighting CFPS's potential for producing other antigens even if this candidate wasn't successful.
Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.
Appl Microbiol Biotechnol
October 2024
Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.
Article Synopsis
- A study found that a specific peptide from the SARS-CoV-2 spike protein (S(1144-1156)) can broadly neutralize multiple COVID-19 variants, including Delta and Omicron.
- Mice vaccinated with this peptide produced high levels of specific antibodies and immune responses, indicating its potential as a vaccine candidate.
- Enhanced neutralizing antibody responses were also seen with slightly modified peptides (S(1143-1157) and S(1142-1158)), suggesting improvements in vaccine design for COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!